PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Articles
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Articles
  • Our team
  • Join us

OpenAI’s large language model (LLM) patents

  • Sector: AI drug discovery
  • 29th April 2025
For tech innovators seeking to understand evolving intellectual property strategies, OpenAI's recent pivot offers essential guidance: far from relying solely on trade secrets, the AI leader is now aggressively pursuing and accelerating patent grants, signaling a significant shift.
 

OpenAI’s approach to IP is often cited in the tech industry as an example of a radically new approach to IP. OpenAI has the reputation for protecting its innovations through the use of trade secrets as opposed to patents. However, it appears that this characterisation of OpenAI’s strategy is years out of date.

This is perhaps not surprising, given that patent applications are not published until 18 months after they are filed, and that OpenAI’s major innovation of ChatGPT was first released about 2 years ago. This year, eleven OpenAI patents and patent applications have been published. Intriguingly, OpenAI is not just filing patents, it is pursuing highly accelerated grant of its patents. This strategy implies that OpenAI has the intention to enforce its IP or at the very least wants the ability to do so. 

Who are OpenAI?

OpenAI began life in 2015 as a non-profit company, with the self-proclaimed vision of providing humanity with safe and beneficial AI. The company famously kick-started a paradigm shift in AI tech in 2022, with the release of its large language model (LLM), ChatGPT. ChatGPT was a revolutionary generative AI model designed to interpret and generate human-like text. Critically, both the inputs and outputs of ChatGPT are in natural language, effectively democratising the use of AI. 

OpenAI’s shift to a more commercial model began in 2019, with the creation of its profit-based subsidiary OpenAI Global, LLC, Since then, Microsoft has invested approximately US$13 billion into OpenAI and owns nearly 50% of its equity. This year, the tech space has been alive with rumours that OpenAI is now planning a shift to a fully profit-based model. Every big tech company also now has their own version of ChatGPT, and there are countless other companies implementing ChatGPT in a vast range of business solutions. 

OpenAI is pursuing speedy patent grant

Fascinatingly, OpenAI is pursuing highly accelerated grant of its IP. A patent can only be enforced once it is granted. However, it can take 3 to 5 years of patent prosecution before national patent offices to achieve grant of a patent. There are also a number of formal prosecution procedures that delay the process. Claiming priority from a first initial filing can provide up to 12 months of additional patent protection, but delays grant of the application by the same amount. Filing an international PCT application reduces costs and can help with efficient multi-jurisdictional prosecution, but will also take longer than pursuing a direct national filing. Therefore, the quickest way to achieve grant of your patent in a particular country is to pursue a direct national filing, possibly even dispensing with a priority claim. Whilst this may have disadvantages in terms of cost and sacrifice of patent term, it can provide you with a granted patent in less than a year. 

All of the currently published applications filed by OpenAI are US cases. Nine of these cases have already been granted. In some cases the time between the filing date and grant was as little as nine or ten months. Furthermore, some of these cases are direct national US filings that do not claim priority. Given the sacrifice of patent term associated with this strategy, OpenAI’s approach strongly suggests that quick grant is a priority for them. At the moment, we can only speculate why this may be the case. The most obvious reason would be that OpenAI intends to enforce its patents and/or to use them as negotiating chips in licensing negotiations. It is also clear from the public databases that OpenAI is pursuing global protection, however these patent applications have not yet been published or granted. 

A closer look at the OpenAI patents

Focusing just on the granted US patents, the claim scope achieved by OpenAI is remarkably broad. The patents relate to generalisable use cases for language models. The OpenAI patents relate to the use of large language models for generating and editing text (US11983488B1, US11886826B1), images (US11922550B1, US11983806B1, US12039431B1), and code (US12008341B2). There are also cases covering methods for integrating language modes with an external API or graphical user interface (US11922144B1, US12051205B1). 

Importantly, the scope of a patent is determined by the language of the granted claims. To infringe a patent claim, a method or product must possess every feature listed in that claim. For example, US11983488B1, relating to the generation and editing of text, specifically covers: 

10. A method for automatically generating and editing text, comprising: 

    receiving an input text prompt, the input text prompt comprising a null set;

    receiving one or more user instructions;

    determining a set of model parameters based on the one or more user instructions;

accessing the language model using the at least one processor based on the input text, the set of model parameters, and the one or more user instructions;

generating, using the accessed language model, an output text based on the input text, the one or more user instructions, and at least one of a sampling temperature parameter or a nucleus sampling parameter;

    receiving one or more new user instructions;

editing the output text based on the language model and the one or more new user instructions by     replacing at least a portion of the output text; and

optimizing the accessed language model by aligning the language model based on the output text using machine learning;

wherein:

    the language model is optimized through one or more iterative cycles of training based on one or more outcome metrics associated with the output text and one or more datasets; and

the one or more datasets comprise at least one of annotated data, labeled data, enriched data, or demonstration data based on one or more output text.

The claims of the other granted patents can be read on Google Patents. Importantly, it is not necessary to include the code for a model in a patent. The description sections of the patents therefore just broadly describe the architecture and training methods for the models, as well as providing examples of their use. 

Final thoughts

For the past 2 years, OpenAI has therefore been busy filing patent applications for the key use cases of ChatGPT. So much for an IP policy based solely on trade secrets! Ironically, however, ChatGPT itself does not yet appear aware of the shift in its owner’s strategy. Today, when asked “Does OpenAI have any patents?”, ChatGPT 4o returned: “As of now, OpenAI does not hold any patents. This approach aligns with its broader strategy of promoting transparency and responsible AI development while avoiding the traditional IP model that might hinder collaboration or the ethical use of AI technology“. Aside from the clear factual inaccuracy of this statement, I also disagree with ChatGPT’s implication that patenting does not align with a goal of transparent or responsible AI development. After all, patents must be published, whereas trade secrets, by definition, are not disclosed. The fact that OpenAI is following other tech companies by patenting their innovations should also come as no surprise. The patent system is a well-established, robust and effective way to protect innovation, and it makes sense for OpenAI to make full use of it. 

This post is based on a previous article on IPKat.

Related insights...

Is it time for patent offices to enter the bioinformatic age?

  • 13th June 2025
In a world in which incalculable amounts of sophisticated sequence data is freely available, are the clunky processes necessary to input patent sequence data really fit-for-purpose?

Alnylam v. Moderna and the judicious use of definitions: The European perspective

  • 10th June 2025
When drafting a patent, seemingly innocuous “boilerplate” definitions in the description can drastically narrow your claims, as demonstrated by the Alnylam v Moderna case in the US, highlighting the critical need for precise language to protect your invention.

All to play for in CRISPR “first-to-invent” US patent battle as Federal Circuit instructs PTAB to reconsider (Regents v. Broad Institute, Nos. 22-1594, 22-1653)

  • 28th May 2025
Navigating the complex CRISPR patent landscape remains a challenge. The Federal Circuit’s decision in Regents v. Broad Institute is another in the ongoing battle between the inventors of CRISPR.

An LLM is not (yet) a person skilled in the art (T 1193/23)

  • 20th May 2025
The EPO clarifies that an LLM interpretation of a technical term in a patent is not yet evidence of how a skilled person would interpret the term.

Strict US written description requirement applied to CAR-T-cell therapy (Juno v Kite)

  • 29th April 2025
The decision in Juno v Kite is not a surprise in light of the recent CAFC case law on written description for antibodies, and represents yet another nail in the coffin of functional genus claiming for biomolecules in the US.

No back-pedalling on prosecution disclaimers (Azurity v. Alkem, Fed. Cir. Case No. 23-1977)

  • 22nd April 2025
In Azurity v. Alkem  the US Court of Appeals for the Federal Circuit (CAFC) affirmed the District of Delaware’s ruling that Alkem’s antibiotic formulation did not infringe patent claims owned by Azurity. The CAFC found that Azurity clearly and unmistakably disclaimed the presence of a key ingredient from the claimed formulation during prosecution. Given that Alkem’s formulation included this ingredient, the generic…

New USPTO Guidance on the use of AI in precision medicine

  • 17th September 2024
The USPTO recently issued Guidance on the patentability of AI. In the US, claims directed solely to a “judicial exception”, in the form of an abstract idea, natural phenomena, or law of nature, are not eligible for patent protection (35 U.S.C. 101). However, the case law on subject matter eligibility is infamously difficult to apply. The new Guidance seeks to provide some clarity…

“Using AI tools to help assess inventive step”: A response to the CIPA journal article

  • 16th July 2024
The cover article of the May 2024 edition of the CIPA Journal proposed a new test for inventive step using AI. The article was inspired by the EPO’s AI assisted search tool, AI-PreSearch. The CIPA journal article proposes to use an AI derived measurement of semantic similarity between the claims and the prior art as a new test for…

When is the inventor of an AI model also an inventor of the model’s output? A closer look at the USPTO Guidance for AI-Assisted Inventions

  • 16th July 2024
According to the USPTO guidance for AI-assisted inventions, AI has the potential to solve some of society’s most difficult challenges. However, in the patent realm, the USPTO also believes that “inventorship analysis should focus on human contributions, as patents function to incentivize and reward human ingenuity”. How then are AI-generated inventions to be protected? As previously reported,…

Don’t shoot yourself in the foot: European file history in US patent claim interpretation (K-fee v Nespresso)

  • 1st February 2024
In the US, the principle of file wrapper estoppel is well established. Submissions made in US patent prosecution may be highly influential for claim interpretation post-grant. Additionally, as recently highlighted in K-fee v Nespresso (Case No. 22-2042, Fed. Cir. Dec. 26, 2023), file wrapper estoppel in the US does not stop at the US file wrapper. Submission made in other…
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2025 All Rights Reserved

Keep in touch

Subscribe

Contact Us